Hologic (NASDAQ:HOLX) experienced a more than 6% increase in its share price intra-day today, following the announcement of its fourth-quarter results. The company reported an earnings per share (EPS) of $0.89, surpassing the Street estimate of $0.84. However, its revenue saw a slight year-over-year decrease of 0.8%, amounting to $945.3 million, yet still exceeded the Street estimate of $940.03 million.
CEO Steve MacMillan commented on the results, highlighting the company’s remarkable performance for fiscal 2023. He emphasized the continued strong growth, noting that each of the company’s divisions experienced double-digit organic growth in the quarter and for the full year, with the exclusion of impacts related to COVID-19.
Looking into the first quarter of 2024, Hologic expects its EPS to be between $0.92 and $0.97, which compares favorably with the Street estimate of $0.94. The company also forecasts its revenue for the quarter to be in the range of $960 million to $985 million. This projection, however, falls short of the Street estimate of $1.017 billion.
For the entire fiscal year, Hologic anticipates its EPS to be in the range of $3.90 to $4.10, compared to the Street estimate of $3.90. The company’s expected revenue for the year is projected to be between $3.92 billion and $4.02 billion, which is below the Street estimate of $4.023 billion.